Opus Genetics, Inc. announced 3 abstracts were presented at the 2026 ASCRS Annual Meeting. In the presentation, "Phentolamine Ophthalmic Solution Provides Durable Improvement in Distance Corrected Near Vision for Presbyopic Patients in a phase 3 Study," the authors provided full results from VEGA-3, a phase 3 study evaluating phentolamine ophthalmic solution (POS) 0.75% for presbyopia. The primary endpoint was the percentage of subjects gaining ≥3 lines of distance corrected near visual acuity(DCNVA) with loss of <5 letters binocular best corrected distance visual acuity (BCDVA) at Day 8. DCNVA, distance corrected intermediate visual acuity (DCIVA), and safety were assessed at multiple time points through Week 6. 

At Day 8, 27% of POS-treated subjects gained ≥15 letters in DCNVA without significant BCDVA loss vs 12% in the placebo group (p<0.0001), meeting the primary endpoint. A statistically significant difference was observed as early as 1 hour post dosing (21% POS vs 6% placebo; p<0.001) and across all visits. POS treated subjects also showed a statistically significant improvement in mean DCIVA at all time points. In addition, there was no evidence of tachyphylaxis over 6 weeks of repeated dosing. Adverse events (AEs) were mostly mild and transient. Most frequent POS AEs were conjunctival hyperemia (26%), eye irritation (5.6%), instillation site irritation (15%), and dysgeusia (5.9%). Headache was only 2.6%. The authors concluded that phentolamine ophthalmic solution demonstrated rapid, sustained, and clinically meaningful improvements in near vision in presbyopic patients. The treatment was well tolerated, with a favorable safety profile and no evidence of tachyphylaxis over 6 weeks of dosing.

In another presentation, "Optical Impact of Reversing Pharmacologically Induced Mydriasis on Image Quality," the authors discussed a post-hoc analysis of MIRA-2, a phase 3 study evaluating the optical impact of Ryzumvi for reversing pharmacologically-induced mydriasis. Across all 3 mydriatics, pharmacological dilation resulted in increased pupil diameter (4.73 to 7.33 mm and 5.05 to 7.40 mm) and decreased AA (5.72 to 4.01 D and 7.54 to 4.63 D) which correspondingly decreased image quality (IQ) from baseline pre-dilation levels (TFareaMTF of 3.37 and 3.43) for phentolamine and placebo, respectively. Following dilation, IQ returned more rapidly to pre-dilation levels with phentolamine (TFareaMTFs of 1.75, 2.26, 3.01, 3.85, 4.29) compared to placebo (TFareaMTFs of 1.94, 2.08, 2.32, 2.77, and 3.06 at 0, 1, 2, 4, and 6 hrs, respectively). IQ with placebo had not returned to pre-dilation levels after 6 hrs. The authors concluded that dilation reversal treatment with 0.75% phentolamine results in earlier recovery and greater improvement of IQ compared with placebo.

Finally, in "Phase 3 Randomized Controlled Study of Phentolamine Ophthalmic Solution in Post-Refractive Surgery Patients with Impaired Mesopic Vision," the authors provided results from LYNX-2, a phase 3 study evaluating phentolamine ophthalmic solution 0.75% for visual disturbances in low light conditions in post-refractive surgery patients. The primary endpoint was the percentage of subjects with ≥3 lines (15 letters) of mesopic low contrast vision (mLCVA) improvement at Day 15. Tachyphylaxis of POS was evaluated at Week 6.

According to the authors, the primary endpoint was met, with 17% of subjects in the phentolamine group achieving ≥15-letter mLCVA improvement at Day 15 vs 9% in the placebo group (p<0.05). A statistically significant difference was also seen at Day 8 (16% vs 8%, p<0.05). The 90% confidence interval in change from baseline in mean mLCVA between Day 3 (best response) and Week 6 in the POS arm did not include the prespecified 5 letter loss, demonstrating no tachyphylaxis. Treatment was well tolerated, and no treatment related serious ocular AEs were reported.

The authors concluded that phentolamine ophthalmic solution significantly improved mLCVA in post-keratorefractive surgery subjects with reduced mLCVA and may represent a potential therapeutic option for this underserved population.